Scientific Advisory Board:
Guiding Our Strategies to Advance Transformative Drugs

Our Scientific Advisory Board provides expert guidance on drug development strategies to advance Chimeron Bio’s pipeline and help bring transformative drugs to patients in need.

Dominique Gouty, Ph.D.

Dr. Dominique Gouty brings over 25 years of business leadership experience in multi-national Pharmaceutical/Healthcare and Services industries, spanning R&D, clinical operations, diagnostics, manufacturing of Biologics and Bioanalytical testing of Protein Drugs, Cell Therapies and Gene Therapies.

Show More

Dr. Gouty most recently served as the Chief Scientific Officer at BioAgilytix, a contract research laboratory. Over her tenure she participated in successfully bringing half of all the biologic drugs (including gene and cell therapies) to final approval by the FDA.  Before this she led an international pharma division of a contract research laboratory specializing in small and large molecule services. Her strategic leadership role led to the building of several market-leading services companies in different locations around the world. Dr. Gouty also has 15 years of prior industry experience with Eli Lilly, J&J, and smaller biotech companies.

Dr. Gouty is a leading expert in novel therapeutic biologics, gene therapy, cell therapy, and biosimilars. She has written several Books and authored over 150 scientific papers covering areas of new drug development/healthcare, and she holds patents on drugs and technologies which have contributed to bringing multiple drugs to market.  Dr. Gouty has a deep and expert knowledge on the evolving regulations of the FDA, EMA, and other regulatory agencies.

Show Less

Jonathan (Jon) Smith, Ph.D.

Dr. Jonathan Smith is an eminent virologist and currently, Chief Scientific Officer at VLP Therapeutics.  He has over thirty-five years of experience in basic virology, infectious disease research, and vaccine development spanning the industry, government and academic laboratories.

Show More

Currently, the Chief Scientific Officer at VLP Therapeutics, Dr. Smith brings over 35 years of experience in virology, infectious diseases research and vaccine development with a focus on RNA-replicon vaccines. Dr. Smith was the former Chief of the Department of Virology, United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and co-founder of AlphaVax, Inc., a biotech focused on RNA vaccines for infectious diseases and cancer. He has also held leadership positions at multiple biotech companies including VP for Development, Operations and Research at ClearPath Vaccines, Executive VP and Chief Scientific Officer at PaxVax Inc., and Chief Scientific Officer at Liquidia Technologies. Dr. Smith has led preclinical and translational programs for a range of infectious agents including Klebsiella, Pseudomonas, Cholerae, HIV, Influenza, Chikungunya, Anthrax, Dengue, Malaria and Zika. Dr. Smith has over 100 publications and multiple issued and pending patents in this field.

Show Less

Robert (Bob) Willette, Ph.D.

Dr. Robert Willette is an eminent discovery pharmacologist, a pharmaceutical industry veteran and a cardiovascular and metabolic disorders expert. He is the founder and president of POC Pharma Consulting, offering strategic advice to discovery and development companies.

Show More

Previously, Dr. Willette spent over thirty years in the pharmaceutical industry, most recently serving as the Vice President, Head and Senior Fellow of GSK’s Heart Failure & Renal Discovery Performance Unit. During his industry tenure he has led and advanced multiple internal discovery programs and alliances across therapeutic modalities. He is the recipient of American Heart Association’s Robert Seikert award for outstanding contribution to stroke research and the George Koelle award for contributions in Pharmacology. Dr. Willette has authored >150 original peer reviewed research papers and his other notable accomplishments include President of the Mid-Atlantic Pharmacology Society, adjunct professorship at Thomas Jefferson University, scientific advisor to the Nephcure Foundation and he currently serves as an industry mentor at the University of Pennsylvania, interim CSO at Complexa Therapeutic, Inc. and consulting CSO at ImmunoMet, Inc.

Dr. Willette received his doctoral degree from the Department of Pharmacology at Rutgers University, School of Medicine and Dentistry in New Jersey and pursued his postdoctoral training in cardiopulmonary biology at the Veterans Administration in NJ and Department of Neurosurgery at Rutgers University and in neurobiology at the Weill Medical College, Cornell University.

Show Less

What Makes ChaESAR™ Compelling?

See how we’re building on the modern science of RNA and our novel technology to develop saRNA therapies that can achieve superior patient response at a lower dose.

About Self-Amplifying RNA